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Abstract
Introduction: In critically ill patients, it is uncertain whether exposure to older red blood cells (RBCs) may
contribute to mortality. We therefore aimed to evaluate the association between the age of RBCs and outcome in
a large unselected cohort of critically ill patients in Australia and New Zealand. We hypothesized that exposure to
even a single unit of older RBCs may be associated with an increased risk of death.
Methods: We conducted a prospective, multicenter observational study in 47 ICUs during a 5-week period
between August 2008 and September 2008. We included 757 critically ill adult patients receiving at least one unit
of RBCs. To test our hypothesis we compared hospital mortality according to quartiles of exposure to maximum
age of RBCs without and with adjustment for possible confounding factors.
Results: Compared with other quartiles (mean maximum red cell age 22.7 days; mortality 121/568 (21.3%)),
patients treated with exposure to the lowest quartile of oldest RBCs (mean maximum red cell age 7.7 days;
hospital mortality 25/189 (13.2%)) had an unadjusted absolute risk reduction in hospital mortality of 8.1% (95%
confidence interval = 2.2 to 14.0%). After adjustment for Acute Physiology and Chronic Health Evaluation III score,
other blood component transfusions, number of RBC transfusions, pretransfusion hemoglobin concentration, and
cardiac surgery, the odds ratio for hospital mortality for patients exposed to the older three quartiles compared
with the lowest quartile was 2.01 (95% confidence interval = 1.07 to 3.77).
Conclusions: In critically ill patients, in Australia and New Zealand, exposure to older RBCs is independently
associated with an increased risk of death.
Introduction
Anemia is extremely common in the critically ill [1] and
is associated with poor outcomes [2-5]. It is therefore
not surprising that 19 to 53% of all patients admitted to
adult ICUs receive at least one unit of allogeneic red
blood cells (RBCs) [1,6-8].
Several publications have highlighted that the adminis-
tration of RBCs and the hemoglobin trigger used for the
administration of RBCs may affect patient morbidity
and mortality [9-18]. More recently, the age of RBCs
has been the focus of concern as a potential cause of
increased morbidity and mortality [10]. A recent review
summarizing data from 27 different studies in adult
patients, however, concluded that it is difficult to deter-
mine whether there is a relationship between the age of
transfused RBCs and mortality [19].
The mechanism responsible for the possible adverse
effects of RBCs may relate to the development of storage
lesions over time. During storage, in a way that increases
over time, important biochemical changes occur: a reduc-
tion in 2,3-diphosphoglycerate, hypocalcemia, cell lysis,
release of free hemoglobin, changes in nitric oxide levels,
alterations in pH [20,21], and increases in lipids [22],
complement [23] and cytokines [24]. These changes are
accompanied by increased membrane fragility, which can
compromise microcirculatory flow and lead to increased
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cytokine release [20,21]. Such changes, which serve as
potential explanations for more unfavorable outcomes,
m a yb ep a r t i c u l a r l yd i s a d v a ntageous to critically ill
patients with a higher mortality risk. In this group, indir-
ect evidence has linked the transfusion of older RBCs
with adverse clinical consequences [25]. Unfortunately,
all such evidence has been retrospective and/or focused
on specific patient groups. The robustness of the rela-
tionship between the age of RBCs and adverse clinical
outcome is thus limited both in strength and generaliz-
ability. Yet if this link exists, the public health conse-
quences are great, given that the transfusion of RBCs is a
common treatment in the critically ill. Furthermore,
exposure to even a single unit of older RBCs might be
associated with unfavorable outcome independent of the
effect of volume of transfused RBCs and other confound-
ing factors.
Accordingly, we hypothesized that the maximum age
of RBCs to which a critically ill patient had been
exposed would have an independent relationship with
hospital mortality. We tested this hypothesis by con-
ducting a prospective multicenter observational study in




We performed a prospective multicenter observational
study in Australian and New Zealand ICUs. All sites
that were members of the Australian and New Zealand
Intensive Care Society (ANZICS) Clinical Trials Group
were invited to participate, and 47 centers agreed to col-
lect data. Each center obtained local Institutional Ethics
Committee approval. Informed consent was waived at
all sites. Over a 5-week period (August to September
2008) all new adult patients admitted to the ICU who
received RBCs were included. Patients remained in the
study until hospital death or discharge.
Patient-specific data included the following: date and
time of hospital and ICU admission, gender, age, Acute
Physiology and Chronic Health Evaluation (APACHE) III
diagnostic code and score, and pre-existing or currently
active co-morbidities. Any type of blood component
given within 24 hours prior to ICU admission or during
the ICU stay was recorded. The date, time and patient
status (alive or dead) at hospital discharge were also
noted. RBC-specific data included the age of the RBC
unit at the time of transfusion and the leukodepletion
status. The age of the blood was determined by subtract-
ing the date of collection from the date of transfusion.
The donation number (this number is unique to each
blood donation) for every unit transfused was noted:
these numbers were used to gather information specific
to each RBC unit from the Australian Red Cross Blood
Service and the New Zealand Blood Service.
Data management
Data were collected using case report forms, which were
completed at sites and then faxed to the study coordi-
nating centre at the ANZIC Research Centre, Monash
University, Melbourne, Australia. The case report forms
were subsequently scanned to a database using an opti-
cal reader. After checking the data and repeated queries
to the study sites, the missing data related to RBC trans-
fusions constituted <1%.
Statistical methods regarding analysis of age of RBCs
Maximum age of RBCs
The relationship between hospital mortality and maxi-
mum age of RBCs received was determined using logistic
regression. We chose the maximum age of RBCs trans-
fused as the independent variable to be tested because we
reasoned that exposure to even a single transfusion of old
RBCs may have a toxic effect and contribute to increased
mortality. Furthermore, we reasoned that once exposure
to red cells with storage lesions occurs, it may cause irre-
versible damage and influence morbidity and mortality.
The association, if present, may therefore not be linear in
nature. First, we tested the age of RBCs as a continuous
variable. Second, according to the literature [26], the
maximum age of RBCs was divided into quartiles to
include a sufficient number of patients in each group,
with the lowest quartile representing the freshest possible
RBCs.
Adjustment for confounding factors
From a univariate analysis, a list of biologically plausible
and statistically significant confounders were identified,
including severity of illness (APACHE III score), leukode-
pletion status, pre-ICU transfusions, cardiac surgery,
other transfused blood components, and pretransfusion
hemoglobin concentration preceding the first transfusion.
We further adjusted for clustering of study sites. The
APACHE III scores were first obtained by linkage of the
study database with the ANZICS Adult Patient Database
and were available for 432 study patients. Second, multi-
ple requests for the missing APACHE III scores were
sent retrospectively to the study sites, ending up with 713
surviving patients (94.2%) and 141 out of 146 patients
who died (96.6%) with an APACHE III score (compared
with <1% of missing values in other study data). Hospital
discharge status was re-checked at the same time.
Finally, given a possible relationship between exposure
to older blood and increased mortality, we sought to
further explore this relationship. A series of binomial
variables were created for each possible maximum age
of blood (<2days, <3days, and so forth), and a cumula-
tive graph was plotted indicating the mortality rate for
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tionship between mortality and the maximum age of red
blood, we also provided a plot of the predicted risk of
death (as derived from the multivariate logistic regres-
sion model) against the maximum age of RBCs, and a
locally weighted nonparametric smoother (LOWESS)
was fitted to the data. LOWESS fits simple models to
localized subsets of the data to build up a function that
describes the deterministic part of the variation in the
data, point by point.
Statistical analysis
Statistical analysis was performed using SAS version 9.1
(SAS Institute Inc., Cary, NC, USA). Descriptive statis-
tics were computed separately for all study variables for
all study patients. Univariate analysis was performed
using chi-square tests for equal proportions, Student t-
tests for normally distributed outcomes and Wilcoxon
rank-sum tests otherwise, with results reported as per-
centages (n), means (standard errors), or medians (inter-
quartile ranges). The results from logistic regression
analysis were reported as odds ratios (ORs) (95% confi-
dence interval (CI)). Two-sided P = 0.05 was considered
statistically significant.
Multivariate logistic regression models were con-
structed using both stepwise selection and backward
elimination procedures with statistically significant cov-
ariates (P < 0.05) remaining in the model. Models
included the identified list of covariates firstly using the
maximum age of blood as a continuous variable and
then secondly as a predetermined categorical variable in
quartiles. The final model was further assessed for
goodness of fit (Hosmer-Lemeshow test), points of
influence (standardized differences in parameter esti-
mates due to deleting the corresponding observation)
and clinical and biological pla u s i b i l i t y .T oe n s u r et h a t
the relationship between the maximum age of blood
and mortality did not differ for specific subgroups,
interactions between the age of RBCs and all other cov-
ariates were explored.
Results
Patients and participating centers
A total of 47 ICUs participated in the study (Australia, n
=3 6 ;N e wZ e a l a n d ,n = 11). All ICU types were repre-
sented: 28 tertiary ICUs, 10 metropolitan ICUs, four
rural ICUs and five private ICUs.
In total, 757 patients received one or more units of
RBCs. Their demographic and clinical data are shown in
Table 1. According to their APACHE III diagnostic clas-
sification, 416 (55.0%) were operative patients and 341
(45.0%) were nonoperative patients. The largest diagnos-
tic groups were cardiac surgery patients (194, 25.6%),
bacterial pneumonia (36, 4.8%), septic shock or sepsis
(56, 7.3%), gastrointestinal neoplasm (23, 3.0%), nono-
perative gastrointestinal bleeding (21, 3.2%), trauma (50,
6.6%), and operative gastrointestinal bleeding (15, 2.0%).
The number of transfusions and the age of RBCs are
included in Table 1.
Age of RBCs and hospital mortality
The mean (median, standard error) pretransfusion
hemoglobin level was 7.8 (7.7, 0.03) g/dl. The ages of
the oldest RBCs and unadjusted hospital mortalities for
the quartiles of the whole study population (n = 757),
and hospital mortalities for the quartiles of those
included in the multivariate analysis (n = 713) according
to maximum RBC age, are shown in Table 2. The hospi-
tal mortality in the lowest quartile (Quartile 1) was 25/
189 (13.2%) versus 121/568 (21.3%) in Quartiles 2 to 4,
with a significant (P = 0.01) unadjusted absolute risk
reduction of 8.1% (95% CI = 2.2 to 14.0%) in hospital
mortality.
Adjustment for confounding factors
In these 713 patients, there was no significant indepen-
dent association with hospital mortality and the maxi-
mum age of RBCs as a continuous variable (univariate
OR 1.02, 95% CI = 1.003 to 1.04, P = 0.025; multivariate
OR = 1.02, 95% CI = 0.99 to 1.04, P =0 . 1 5 ) ,b u tt h e r e
was a statistically significant difference in mortality
between quartiles of maximum age of RBCs at both the
univariate level (P = 0.01) and the multivariate level (P
= 0.03). Day 11 was the 25th percentile of the oldest
RBC transfused (not the 25th percentile of all transfused
RBCs). When compared with the lowest quartile (Quar-
tile 1), exposure to the combination of three quartiles
(Quartiles 2 to 4) of maximum age of RBCs was asso-
ciated with an increased risk of hospital mortality
(adjusted OR = 2.01, 95% CI = 1.07 to 3.77). Other vari-
ables independently associated with hospital mortality
were APACHE III score, fresh frozen plasma transfu-
sion, pretransfusion hemoglobin level, and cardiac sur-
gery (for ORs see Table 3). The study site (clustering),
leukodepletion status, number of RBC transfusions and
pre-ICU transfusions (RBCs, platelets, fresh frozen
plasma yes/no) did not show an independent association
with hospital mortality.
The area under the curve for the multivariate model
was 0.86, and a Hosmer-Lemeshow P =0 . 9 3s u g g e s t e d
the model adequately fitted the data. A graphic trend
for the adjusted hospital death according to the maxi-
mum age of RBCs is presented in Figure 1 for illustra-
tion. There were no significant interactions between the
maximum age of blood and all other variables in the
multivariate model. In addition, the predicted risk of
death against the maximum age of RBCs with LOWESS
is presented in Figure 2.
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We conducted a prospective observational study in 47
ICUs in Australia and New Zealand to assess the asso-
ciation between age of RBCs and outcome. In critically
ill patients receiving RBCs, we found an association
between exposure to older red cells and increased hospi-
tal mortality rate. This association remained after adjust-
ment for potential confounding factors.
In this study, the mean age of all RBCs was 16.2 days
and the oldest RBC unit given to each patient was 19.6
days on average. This compares with 21.2 days in the
United States [1] and 16.2 days in Europe [7]. In 2007,
the mean calculated age of transfused RBCs in the Uni-
ted States was 19.5 days, although just 7.8% of the hos-
pitals reported such data [27]. Our results, therefore, are
in agreement with the mean age of RBCs in previous
studies and in other countries.
The mean pretransfusion hemoglobin values in pre-
vious studies - namely 8.6 g/dl in the United States [1]
and 8.4 g/dl in Europe [7] - are in line with our mean
pretransfusion hemoglobin concentration. In a previous
study in Australia and New Zealand conducted in 2001
by French and colleagues the median pretransfusion
hemoglobin level was 8.2 g/dl [6], compared with 7.7 g/
dl in the present study. In keeping with published evi-
dence [9], therefore, Australian and New Zealand trans-
fusion practice appears to have moved toward a more
restrictive approach during recent years.
There is no suitably powered randomized controlled
trial of the effect of age of RBCs on mortality [28].
Moreover, with the exception of cardiac surgery
patients, no prospective cohort study of adequate sample
size has evaluated the possible association between RBC
age and mortality in the critical care setting. In trauma
patients, four small single-center cohort studies have
s u g g e s t e dt h a te x p o s u r et oo l d e rR B C sm a yb ea ni n d e -
pendent risk factor for multiple organ dysfunction [29],
increased infections [14], and increased ICU length of
stay [30] and hospital length of stay [31], but none have
assessed its link with mortality. Our prospective multi-
center cohort study is therefore the first to assess the
independent relationship between the age of RBCs and
hospital mortality in a heterogeneous population of criti-
cally ill patients. Nonetheless, our findings must be seen
in light of three recent large retrospective studies in car-
diac surgery patients [10], in trauma patients [32], and
in a registry of hospitalized patients [33].
Table 1 Patient characteristics (n = 757) and transfusion details
All patients Quartile 1 Quartiles 2 to 4 P value
a
Age (years) 66 (54 to 76) 65 (50 to 74) 66 (54 to 76) 0.16
Male 468 (62%) 112(59%) 356 (62%) 0.40
Cardiac surgery patients 194 (26%) 51 (26%) 143 (25%) 0.62
Trauma patients 50 (7%) 6 (3%) 44 (7%) 0.03
Sepsis patients 56 (7%) 15 (7%) 41 (7%) 0.74
Received pre-ICU
RBCs 333 (44%) 90 (47%) 243 (42%) 0.25
Platelets 130 (17%) 33 (17%) 97 (17%) 0.90
FFP 168 (22%) 48 (25%) 120 (21%) 0.22
RBCs transfused 2 (1 to 4) 2 (2 to 3) 2 (2 to 5) <0.0001
Average age of RBCs 14 (9.5 to 21.5) 7.5 (5.7 to 9.0) 17.6 (12.9 to 24.0) <0.0001
Maximum age of RBCs 18 (11 to 28) 8 (6 to 9) 22 (15 to 30) <0.0001
RBCs leukodepleted 599 (79%) 149 (78%) 450 (79%) 0.91
Pretransfusion
Hemoglobin (g/dl) 7.7 (7.2 to 8.2) 7.6 (7.1 to 8.2) 7.7 (7.2 to 8.2) 0.50
Received platelets 180 (24%) 48 (25%) 132 (23%) 0.55
Received FFP 256 (34%) 57 (30%) 199 (35%) 0.22
ICU length of stay (days) 3.9 (1.9 to 8.6) 3.5 (1.7 to 7.1) 4.2 (1.9 to 9.2) 0.02
Hospital mortality 146 (19.3%) 25 (13%) 121 (21%) 0.015
All values expressed as number (proportion) or median (interquartile range). RBC, red blood cell; FFP, fresh frozen plasma.
aQuartile 1 versus Quartiles 2 to 4.
Table 2 Unadjusted mortality rates according to quartiles
of maximum age of red cells
Quartile Age of RBCs (days) Mortality
All patients APACHE III scored
1 7.7 (2 to 11) 25/189 (13.2%) 24/185 (13.0%)
2 13.8 (11 to 18) 41/189 (21.7%) 40/175 (22.9%)
3 22.6 (18 to 28) 36/189 (19.1%) 34/176 (19.3%)
4 34.4 (28 to 42) 44/190 (23.2%) 43/177 (24.3%)
2 to 4 22.7 (11 to 42) 121/568 (21.3%) 117/528 (22.1%)
Values expressed as median (range) or number/total (proportion). RBC, red
blood cell; APACHE, Acute Physiology and Chronic Health Evaluation.
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colleagues found that patients given older RBCs had an
increase in unadjusted mortality, prolonged ventilation
and increased sepsis, and that the transfusion of older
RBCs was independently associated with an increased
risk-adjusted rate of a composite of serious adverse
events [10]. Although the findings of the above study
are both important and provocative and the sample size
was large, several features of its design made confirma-
tory studies desirable. First, the study was retrospective
with all the inherent shortcomings of such a design.
Second, the study focused only on cardiac surgery
patients. Third, the study excluded more than 28% of
patients because those patients received both fresh and
older RBCs. Fourth, the study separated patients into
two groups only according to the age of RBCs using an
arbitrary 14-day cut-off point. Finally, the study did not
adjust for baseline differences, age or number of units
transfused before ICU treatment, and combined intrao-
perative and postoperative RBC transfusions [26,34].
Recently, Weinberg and colleagues demonstrated a
higher mortality among trauma patients who received at
least three RBC units [32]. In concordance, the largest
registry study in recipients of RBC transfusion from
1995 to 2002 by Edgren and colleagues suggested that
RBCs older than 30 days were associated with an
increased risk of death in a 2-year follow-up [33].
Whilst impressive in sample size the retrospective reg-
istry studies have been performed mostly outside the
critical care setting with a lower expected mortality rate
and, thus, a lesser ability to detect relative reduction in
risk. Therefore, because of the limitations of the pre-
vious studies and the public health importance of this
issue, we considered it desirable to conduct a prospec-
tive, multicenter study to confirm or refute these find-
ings in a broader population of critically ill patients.
We initially found a difference in unadjusted mortality
rates according to the maximum age of red cells to
which a patient had been exposed: the quartiles with
older red cells were associated with a clear increase in
mortality when compared with the lowest RBC quartile.
However, we reasoned that this difference required cor-
rection for illness severity. Accordingly, to more rigor-
ously test the validity of our findings, we performed
multivariate analysis in these patients. We adjusted for
both APACHE III score, number of transfusions, pre-
ICU transfusions, fresh frozen plasma and platelet trans-
fusions, leukodepletion status, pretransfusion hemoglo-
bin concentration, clustering of study sites, and cardiac
surgery, and we used hospital mortality as the depen-
dent variable and found a significant and independent
association between the maximum age of red cells to
which a patient had been exposed and mortality. Our
findings indicating an association between exposure to
older RBCs and increased mortality are in broad agree-
ment with the results of the three large retrospective
studies [10,32,33], and with a post hoc analysis of a ran-
domized controlled trial in critically ill children by Gau-
vin and colleagues [35]. The association between higher
Table 3 Univariate and multivariate logistic regression analysis in patients with APACHE III scores
Variable Unadjusted Multivariate
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
APACHE III score (one point) 1.03 (1.02 to 1.04) <0.0001* 1.04 (1.03 to 1.05) <0.0001*
RBC units transfused (number) 1.09 (1.05 to 1.13) <0.0001* 1.02 (0.97 to 1.08) 0.45
Platelet transfusion (yes/no) 1.79 (1.20 to 2.67) 0.005* 1.17 (0.58 to 2.34) 0.66
FFP transfusion (yes/no) 2.10 (1.44 to 3.05) 0.0001* 1.98 (1.16 to 3.38) 0.01*
Cardiac surgery (yes/no) 0.21 (0.11 to 0.39) <0.0001* 0.31 (0.14 to 0.71) 0.006*
Pretransfusion hemoglobin (per g/dl) 1.02 (1.00 to 1.04) 0.04* 1.06 (1.03 to 1.09) 0.0001*
Older quartiles versus freshest quartile of maximum RBC age 1.87 (1.17 to 2.99) 0.01* 2.01 (1.07 to 3.77) 0.03*
Leukodepletion 1.12 (0.71 to 1.77) 0.61 0.88 (0.34 to 2.24) 0.78
Study site 0.12 0.30
APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; FFP, fresh frozen plasma; RBC, red blood cell. *Significant variable (P < 0.05).
Figure 1 Hospital mortality according to maximum age of red
blood cells. Hospital mortality (%, 95% confidence interval)
according to the maximum age of red blood cells (RBCs) (days).
Patients with the maximum age of RBCs exceeding each cut-off
point are excluded.
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physician attempts to compensate for more severe
underlying disease (for example, chronic pulmonary or
cardiovascular or cerebrovascular disease) or ongoing
bleeding.
The present study has several strengths. The investiga-
tion was a prospective, multicenter study and included a
heterogeneous group of critically ill patients, increasing
its generalizability. In addition, the study included multi-
variate adjustment for baseline characteristics, illness
severity and relevant variables using in-hospital mortal-
ity as an endpoint.
The study also, however, has some significant limita-
tions. This study was not a randomized trial, thus any
association detected by multivariate regression analysis
does not imply causation. For example, there may have
been factors that influenced this association of which we
are not aware and were unable to correct for (for exam-
ple, use of vasopressors, PaO2/FiO2 ratios, use of anti-
biotics). Treating clinicians were not blinded to the age
of RBCs. We have no reason to believe, however, that
clinician behavior was influenced by or itself influenced
the age of transfused RBCs, a variable outside their con-
trol. We did not obtain data on red cell transfusion out-
side the ICU. We did not follow-up patients after
hospital discharge to establish their 90-day survival;
such follow-up might have affected our findings. The
study comprised only Australian and New Zealand ICUs
and its findings may not apply to other healthcare
systems. The transfusion practice and the mean age of
transfused red cells, however, appear similar to those
reported in studies from Europe and North America.
The maximum age of red cells was not significantly
associated with hospital mortality when evaluated as a
continuous variable, but had a significant association
when evaluated using quartiles, which can be explained
by the nonlinear association demonstrated in Figure 1.
In addition, our exploratory post hoc analysis suggests
that a linear relationship between the age of blood and
mortality may exist for RCBs with a lower maximum
age (<15 days old), but that, beyond approximately 15
days, the deleterious effects may be less. The missing
linear relationship across the whole range of RBC’sa g e
is biologically plausible given the possibility of a maxi-
mum level of deleterious changes in RBCs over time. It
is also conceivable that the use of a maximum value
may not readily lend itself to a linear relationship.
Finally, the unadjusted difference in hospital mortality
was high, raising some uncertainty about biological
plausibility. In response, we adjusted for all relevant
available confounding factors, expecting the difference
to lose statistical significance; it did not.
Conclusions
We conclude that, in critically ill patients in Australia
and New Zealand who received RBCs, exposure to older
RBCs is independently associated with increased hospital
m o r t a l i t yc o m p a r e dw i t he x p o s u r et oo n l yt h eR B C s
Figure 2 Predicted risk of death against maximum age of red blood cells. A locally weighted nonparametric smoother (LOWESS) for the
predicted probability of death and the maximum age of red blood cells.
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tion now requires further investigation in other geogra-
phical and healthcare jurisdictions, and, if confirmed,
justifies prospective randomized interventional studies
to confirm or refute its impact on patient outcome.
Key messages
￿ Critically ill patients treated with RBCs of the low-
est quartile of maximum age had an unadjusted
absolute risk reduction in hospital mortality of 8.1%
compared with the other quartiles.
￿ This relationship remained significant after adjust-
ment for confounding factors (OR = 2.01, 95% CI =
1.07 to 3.77).
￿ An adequately-sized multicentre randomized con-
trolled trial focusing on the effect of age of RBCs
and mortality in the critically ill is justified.
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